Antibody Information
General Information of This Antibody (ID: ANTI0JOGAB)
| Antibody Name | Anti-CD73 antibody |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | CD73 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
BB-1709 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have histologically confirmed metastatic solid tumors (RECIST 1.1 measurable), ECOG 0-1, and life expectancy ≥12 weeks. Key exclusions include recent anti-cancer therapies (within 2-4 weeks depending on type), active CNS metastases, grade ≥2 neuropathy, uncontrolled infections (HIV/HBV/HCV), pregnancy, or hypersensitivity to BB-1709 components.
Click to Show/Hide
|
||||
| Administration Dosage |
BB-1709 will be administered as an intravenous infusion by Q3W or Q2W as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06241898 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I, Open Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of BB-1709 in Patients With Locally Advanced/Metastatic Solid Tumors
|
||||
| Primary Endpoint |
The primary safety evaluation focuses on adverse events (AEs) and serious adverse events (SAEs) occurring within 3 years to assess BB-1709's safety profile.
|
||||
| Other Endpoint |
Pharmacokinetic analysis includes area under the serum concentration-time curve (AUC0-inf) measured during Cycles 1-8 (21-day cycles) to characterize BB-1709's exposure.
|
||||
References